February 28th, 2025 – Zug, Switzerland: RGCC International is proud to announce the launch of its latest test, InVyomma Plus. This innovative test marks RGCC’s 14th non-invasive tool, further expanding the company’s commitment to advancing precision oncology and patient care.
InVyomma Plus is designed to provide a comprehensive analysis of the gut microbiome, including the profiling of short-chain fatty acids (SCFAs), and its association with cancer development.
“Research has shown that the microbiome plays a crucial role in the onset and progression of various cancer types,” said Dr. Ioannis Papasotiriou, Founder and Director of RGCC International. “With InVyomma Plus, we enable clinicians to make more informed decisions regarding treatment strategies and overall patient health. This test allows for a more personalized approach to treatment, ultimately improving patient outcomes and quality of life.”
The microbiome can influence cancer progression through various mechanisms. It can act as a direct cancer-transforming agent by producing toxic metabolites and carcinogenic compounds or indirectly contribute to cancer through inflammation, immunosuppression, and its impact on cancer therapy efficacy and toxicity. By analyzing these factors, InVyomma Plus provides valuable data to support tailored treatment plans.
The InVyomma Plus test requires four stool collection tubes—two for gut microbiome profiling and two for SCFA analysis. The analysis period takes approximately 2-3 weeks, with results available within 2-4 weeks after sample arrival at RGCC’s laboratory facilities.
With the launch of InVyomma Plus, RGCC reaffirms its mission to deliver pioneering non-invasive solutions that empower clinicians and patients with actionable insights. This latest addition to the company’s portfolio reinforces its dedication to advancing cancer research and personalized medicine.
About RGCC International:
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For general inquiries, please contact: office@rgcc-international.com